Literature DB >> 11907744

Accumulation of iodized oil within the nonneoplastic liver adjacent to hepatocellular carcinoma via the drainage routes of the tumor after transcatheter arterial embolization.

N Terayama1, O Matsui, T Gabata, S Kobayashi, J Sanada, K Ueda, M Kadoya, Y Kawamori.   

Abstract

PURPOSE: After transcatheter arterial embolization (TAE) with iodized oil (Lipiodol), a relatively dense accumulation of Lipiodol is often seen in the nontumorous liver adjacent to a hypervascular hepatocellular carcinoma (HCC) nodule. We compared this phenomenon with the findings obtained with single-level dynamic CT during hepatic arteriography (SLDCTHA) and presumed its possible mechanism.
METHODS: Fifty-six patients with HCC underwent hepatic angiography including SLDCTHA followed by segmental or subsegmental TAE with a mixture of an anticancer drug and Lipiodol. We compared the drainage area of the HCC depicted on SLDCTHA with the Lipiodol accumulation in the nontumorous liver adjacent to the HCC on CT after TAE (LpCT).
RESULTS: In 26 of the 56 patients, a definite corona enhancement around the HCC, suggesting the drainage of blood from the tumor into the surrounding liver parenchyma, was seen on the late phase of SLDCTHA. In 17 of these 26 patients (65.4%), LpCT showed a more intense accumulation of Lipiodol in the nontumorous liver adjacent to the HCC that corresponded to the drainage area revealed on SLDCTHA.
CONCLUSION: The drainage of blood from the HCC was considered to be a possible mechanism of the accumulation of Lipiodol in the nontumorous liver adjacent to the HCC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11907744     DOI: 10.1007/s00270-001-0070-2

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  16 in total

Review 1.  Transarterial approaches to primary and secondary hepatic malignancies.

Authors:  Ali Habib; Kush Desai; Ryan Hickey; Bartley Thornburg; Robert Lewandowski; Riad Salem
Journal:  Nat Rev Clin Oncol       Date:  2015-05-19       Impact factor: 66.675

Review 2.  Rationale of transcatheter intra-arterial therapies of hepatic cancers.

Authors:  Ryan M Hickey; Robert J Lewandowski; Riad Salem
Journal:  Hepat Oncol       Date:  2014-09-09

3.  Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.

Authors:  Roderich E Schwarz; Ghassan K Abou-Alfa; Jeffrey F Geschwind; Sunil Krishnan; Riad Salem; Alan P Venook
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

4.  Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma.

Authors:  Jin Woo Choi; Jin Wook Chung; Dong Ho Lee; Hyo-Cheol Kim; Saebeom Hur; Myungsu Lee; Hwan Jun Jae
Journal:  Eur Radiol       Date:  2017-12-07       Impact factor: 5.315

Review 5.  Transcatheter intraarterial therapies: rationale and overview.

Authors:  Robert J Lewandowski; Jean-Francois Geschwind; Eleni Liapi; Riad Salem
Journal:  Radiology       Date:  2011-06       Impact factor: 11.105

6.  Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study.

Authors:  Masahito Nakano; Takashi Niizeki; Hiroaki Nagamatsu; Masatoshi Tanaka; Ryoko Kuromatsu; Manabu Satani; Shusuke Okamura; Hideki Iwamoto; Shigeo Shimose; Tomotake Shirono; Yu Noda; Hironori Koga; Takuji Torimura
Journal:  Mol Clin Oncol       Date:  2017-10-04

7.  Iodized oil accumulation in the hypovascular tumor portion of early-stage hepatocellular carcinoma after ultraselective transcatheter arterial chemoembolization.

Authors:  Shiro Miyayama; Osamu Matsui; Masashi Yamashiro; Yasuji Ryu; Harumi Takata; Taro Takeda; Hiroyuki Aburano; Noriaki Shigenari
Journal:  Hepatol Int       Date:  2007-11-14       Impact factor: 6.047

Review 8.  Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization?

Authors:  Eleni Liapi; Jean-Francois H Geschwind
Journal:  Cardiovasc Intervent Radiol       Date:  2010-11-12       Impact factor: 2.740

9.  Atypically enhanced cavernous hemangiomas of the liver: centrifugal enhancement does not preclude the diagnosis of hepatic hemangioma.

Authors:  Masahiro Matsushita; Yasuo Takehara; Hatsuko Nasu; Yuki Hirai; Shuhei Yamashita; Kenichi Souda; Yoshimasa Kobayashi; Katsutoshi Miura
Journal:  J Gastroenterol       Date:  2007-02-06       Impact factor: 7.527

10.  Intermediate hepatocellular carcinoma: the role of transarterial therapy.

Authors:  Fabrizio Chegai; Antonio Orlacchio; Stefano Merolla; Serena Monti; Lorenzo Mannelli
Journal:  Hepat Oncol       Date:  2015-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.